Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Study Finds Almost 4% of Cancers Linked to Obesity

A recent study published in CA: A Cancer Journal for Clinicians, a peer-review journal of the American Cancer Society, links excess body weight to approximately 4 percent of cancers worldwide.

Read More »

Sprayable Gel May Help Fight off Cancer Recurrence After Surgery

A group of researchers with UCLA developed a spray gel that contains immune-stimulating drugs.

Read More »

Benefits of statins far outweigh risks

The benefits of statins in reducing the odds of heart attacks and strokes far outweigh any risks of side effects, according to a scientific statement released by the American Heart Association.

Read More »

Axovant Abandons Another Dementia Drug

Axovant Sciences’ Phase II trial of nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia failed to meet the experimental drug’s primary efficacy endpoint.

Read More »

Scientists to test tailor-made vaccine tech to fight epidemics

A global coalition set up to fight disease epidemics is investing up to $8.4 million to develop a synthetic vaccine system that could be tailor-made to fight multiple pathogens such as flu, Ebola, Marburg and rabies.

Read More »

Generon Presents Positive Phase III Results Of F-627 In Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Generon BioMed Holding Ltd. announced at the annual San Antonio Breast Cancer Symposium (SABCS) positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor protein, designed using Generon’s Dikine technology platform.

Read More »

Exclusive: Orchard CEO Touts Transformative Power of Gene Therapy Following ASH Data Presentation

Orchard Therapeutics is developing a suite of autologous ex-vivo lentiviral gene therapies to correct a rare autoimmune disorder.

Read More »

AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.

Read More »

Supernus’ ADHD treatment meets main goal in studies

Supernus Pharmaceuticals’ experimental drug for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from 6 to 11 years of age in two late-stage studies.

Read More »

AbbVie’s Rova-T Sees Another Failure

AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom